Simulations Plus to Present at 17th Annual Craig-Hallum Institutional Investor Conference
Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will participate in Craig-Hallum’s 17th Annual Institutional Investor Conference on Wednesday, May 27, 2020, beginning at 10:00 a.m. ET.
Each year, Craig-Hallum hosts a multi-industry investor conference in Minneapolis featuring over 130 public companies where institutional clients can meet formally with corporate management. This year’s conference will be virtual and consists of one-on-one conference calls of 30-minutes’ duration. For more information about the conference or to inquire about scheduling a one-on-one meeting with Mr. O’Connor, please contact Hayden IR at [email protected].
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury, drug-induced kidney injury, and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.
Follow us on Twitter | LinkedIn | YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20200521005072/en/
Simulations Plus Aktie
Die Community bevorzugt Simulations Plus mit mehreren Buy-Einschätzungen und keinen Sell-Einschätzungen.
Ein Kursziel von 51 € für Simulations Plus würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 34.0 € bedeuten.
